CUE

Cue BiopharmaD

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-18

Current thesis

The constructive case is that Cue preserves Nasdaq listing, avoids a disorderly financing outcome, and continues extracting non-dilutive value from collaborations such as ImmunoScape and BI, leaving the equity materially above today's distressed micro-cap level if funding pressure eases [#8-K-2026-04-13] [#10-K-2026-03-16].

Posture

Defensive

Lead driver

Momentum

What changed

Momentum remains the lead driver in the composite, 7D delta -4.6.

What can break

Collaboration-related cash inflows, including ImmunoScape timing, may not be sufficient to offset broader funding needs [#10-K-2026-03-16].

Momentum

Value

Sentiment

Setup hits (3d)

0 · Net Neutral

AI TargetsBase $0.38 · Bull $0.85 · Bear $0.14

Data freshness

Prices

As of 2026-07-18

Fundamentals

As of 2026-07-17 • Vendor: Data Vendor v1

Scores

As of 2026-07-18 • Model: HYBRID_IC_RP

AI Memo

As of 2026-04-15 • Model: RankAlpha Sentiment Codex

Investment thesis

As of 2026-07-18

Supporting evidence

What

Grade D · Defensive

Confidence Medium · Net Neutral

Target $115.00

Why

Momentum94 · Δ7d -4.6

Value41 · Δ7d -0.1

Sentiment0 · Δ7d 0.0

So what

Weak posture (Net Neutral). Prioritize risk control and patience.

Lead driver: Momentum · See technicals

Momentum

26% active weight

Current posture

7d trendFlat

Δ7d

-4.6

Δ21d

-6.2

Value

39% active weight

Current posture

7d trendFlat

Δ7d

-0.1

Δ21d

0.0

Sentiment

34% active weight

Current posture

7d trendFlat

Δ7d

0.0

Δ21d

0.0

Why this grade

Composite grade D. Momentum 93.7 / Value 41.1 / Sentiment 0.0

Fundamentals (TTM)

As of 2026-07-17

Market Cap

$130.88M

Beta

1.49

Shares Out

4.2M

P/E (TTM) · Derived

-3.7

P/S (TTM)

4.24

P/FCF (TTM) · Derived

-4.90

Rev YoY

+1250.6%

EPS YoY

-78.3%

Gross Margin

+99.0%

Op Margin

-537.5%

Net Debt

-$22.94M

Current Ratio

3.57

As of 2026-07-18 • Updated nightlySource: Internal modelMethodology